{"id":"bb88a2a4-2f54-51a8-ada2-e73ff90b255d","stable_key":"ff370329-68a3-573d-96ee-597de78a3967:api-chamomile-relapse-null","predicate":"no_detected_change_in_recorded_comparison","statement":"Chamomile continuation did not significantly reduce the primary relapse outcome: 7/46 versus 12/47, hazard ratio 0.52, 95% CI 0.20–1.33, P=0.16.","claim_class":"observational","status":"source_recorded","evidence_grade":"ungraded","direction":"neutral","is_public":true,"mechanism_event_id":"2ecd9e13-3274-5469-aa7e-282f92be2fb0","mechanism_event_label":"Chamomile continuation did not significantly reduce the primary relapse outcome: 7/46 versus 12/47, hazard ratio 0.52, 95% CI 0.20–1.33, P=0.16.","subject":{"id":"1eebe3b2-86dc-50df-8db3-595b07ef847c","slug":"chamomile-extract-gad-2016","display_name":"Chamomile extract in the 2016 anxiety-relapse trial","entity_type_key":"botanical"},"object":{"id":"2ac8e0d2-a251-5e0a-a3e9-ce895e16c56a","slug":"api-human-gad-relapse","display_name":"Anxiety relapse in the 2016 chamomile continuation trial","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"2ecd9e13-3274-5469-aa7e-282f92be2fb0","stable_key":"ff370329-68a3-573d-96ee-597de78a3967:api-chamomile-relapse-null-event","event_type":"experimental_observation","label":"Chamomile continuation did not significantly reduce the primary relapse outcome: 7/46 versus 12/47, hazard ratio 0.52, 95% CI 0.20–1.33, P=0.16.","description":"### api-chamomile-relapse-null\n\nChamomile continuation did not significantly reduce the primary relapse outcome: 7/46 versus 12/47, hazard ratio 0.52, 95% CI 0.20–1.33, P=0.16.\nResponder-enriched design and imprecision limit inference. Secondary symptom scores improved, but they do not replace the null primary outcome.\nModel and exposure: 93 responders randomized after a 12-week open-label phase; 1500 mg extract/day, 26-week continuation.\nLimitations: Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.\nReference: Long-term chamomile (Matricaria chamomilla L.) treatment for generalized anxiety disorder: A randomized clinical trial. | 2016 | https://pubmed.ncbi.nlm.nih.gov/27912875/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC5646235/ | https://doi.org/10.1016/j.phymed.2016.10.012 | Access: Indexed primary abstract/metadata only; unextracted doses, figures and methods remain unknown.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"1eebe3b2-86dc-50df-8db3-595b07ef847c","slug":"chamomile-extract-gad-2016","display_name":"Chamomile extract in the 2016 anxiety-relapse trial","entity_type_key":"botanical"},"role":"tested factor","stoichiometry":null,"state_label":"Continued chamomile extract","sequence_order":0,"notes":""},{"entity":{"id":"2ac8e0d2-a251-5e0a-a3e9-ce895e16c56a","slug":"api-human-gad-relapse","display_name":"Anxiety relapse in the 2016 chamomile continuation trial","entity_type_key":"cellular_process"},"role":"measured outcome","stoichiometry":null,"state_label":"no_detected_change","sequence_order":1,"notes":""}]},"contexts":[{"dimension":"evidence_access","value_text":"Indexed primary abstract/metadata only; unextracted doses, figures and methods remain unknown.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_contrast","value_text":"{\"intervention\": \"Continued chamomile extract\", \"comparator\": \"Placebo after initial response\", \"endpoint\": \"Chamomile continuation did not significantly reduce the primary relapse outcome: 7/46 versus 12/47, hazard ratio 0.52, 95% CI 0.20–1.33, P=0.16.\", \"effect_direction\": \"no_detected_change\", \"combination\": \"single\", \"conditions\": []}","comparator":null,"unit":null,"notes":"Explicit extracted experimental comparison; recorded from source.","entity":null},{"dimension":"experimental_model","value_text":"93 responders randomized after a 12-week open-label phase; 1500 mg extract/day, 26-week continuation.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"interpretation_status","value_text":"Recorded from source with stated access limits; ungraded, not independent replication.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Apigenin collection; exact intervention and molecular form govern interpretation.","comparator":null,"unit":null,"notes":"","entity":{"slug":"apigenin","display_name":"Apigenin","entity_type_key":"small_molecule"}},{"dimension":"plain_language","value_text":"Chamomile continuation did not significantly reduce the primary relapse outcome: 7/46 versus 12/47, hazard ratio 0.52, 95% CI 0.20–1.33, P=0.16.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"Long-term chamomile (Matricaria chamomilla L.) treatment for generalized anxiety disorder: A randomized clinical trial. | https://pubmed.ncbi.nlm.nih.gov/27912875/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC5646235/ | https://doi.org/10.1016/j.phymed.2016.10.012","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"source_locator","value_text":"Reviewed reference api-chamomile-relapse-null; Responder-enriched design and imprecision limit inference. Secondary symptom scores improved, but they do not replace the null primary outcome.","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"a1d3ba09-0bd5-5a80-b796-763896dc5df9","evidence_kind":"source_excerpt","locator":"Lines 820-826","start_line":820,"end_line":826,"excerpt":"### api-chamomile-relapse-null\n\nChamomile continuation did not significantly reduce the primary relapse outcome: 7/46 versus 12/47, hazard ratio 0.52, 95% CI 0.20–1.33, P=0.16.\nResponder-enriched design and imprecision limit inference. Secondary symptom scores improved, but they do not replace the null primary outcome.\nModel and exposure: 93 responders randomized after a 12-week open-label phase; 1500 mg extract/day, 26-week continuation.\nLimitations: Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.\nReference: Long-term chamomile (Matricaria chamomilla L.) treatment for generalized anxiety disorder: A randomized clinical trial. | 2016 | https://pubmed.ncbi.nlm.nih.gov/27912875/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC5646235/ | https://doi.org/10.1016/j.phymed.2016.10.012 | Access: Indexed primary abstract/metadata only; unextracted doses, figures and methods remain unknown.","model_system":"93 responders randomized after a 12-week open-label phase; 1500 mg extract/day, 26-week continuation.","directness":"reported_statement","verification_status":"source_recorded","notes":"Original paraphrase in the retained reviewed reference, not a verbatim primary-paper quotation. Access level is explicit.","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"54eac90b-add1-5f56-9036-d900307c5697","stable_key":"import-ff370329-68a3-573d-96ee-597de78a3967","title":"Apigenin: detailed mechanisms of action (reviewed 10 October 2026)","document_type":"imported_text","citation_label":"AI-assisted original curation of primary studies; claim-local access and experimental limitations stated. Includes original-draft correction history. No independent replication claimed.","file_path":"","sha256":"ede6e5c6b91d66b66844f2ff667a7f8303d9ac1281f15dc09db703f7de4da942","revision_id":"b41a39a2-0197-549c-97a5-1765e6696931","review_status":"source_recorded","notes":""}}],"relations":[{"id":"a10d1a47-2be9-598b-8aff-f80b016538a3","relation_type":"limits_scope_of","notes":"Secondary symptom improvement does not replace the nonsignificant primary relapse endpoint.","source_claim_id":"bb88a2a4-2f54-51a8-ada2-e73ff90b255d","source_claim_key":"ff370329-68a3-573d-96ee-597de78a3967:api-chamomile-relapse-null","source_statement":"Chamomile continuation did not significantly reduce the primary relapse outcome: 7/46 versus 12/47, hazard ratio 0.52, 95% CI 0.20–1.33, P=0.16.","target_claim_id":"e5899fc7-0056-50ae-9fcc-eba5958c8f1c","target_claim_key":"ff370329-68a3-573d-96ee-597de78a3967:api-chamomile-symptoms","target_statement":"The continuation trial reported better secondary anxiety-symptom scores with chamomile, P=0.0032."}],"conflicts":[],"corrections":[],"research":null}